Inovio Ebola vaccine, INO-4212 generates robust immune responses in human in phase I study

Inovio Pharmaceuticals, Inc. announced that its Ebola vaccine, INO-4212, was safe, tolerable, and generated strong T cell and antibody responses in … Full Article http://j.gs/5sTq

Click here to read full article